GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03992014
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1537
- Registration Number
- NCT03980483
- Locations
- 🇬🇧
GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom
Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 290
- Registration Number
- NCT03973905
- Locations
- 🇧🇪
GSK Investigational Site, Wavre, Belgium
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1764
- Registration Number
- NCT03970837
- Locations
- 🇬🇧
GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT03965533
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT03957577
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1351
- Registration Number
- NCT03954743
- Locations
- 🇹🇷
GSK Investigational Site, Kayseri, Turkey
Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03949842
- Locations
- 🇺🇸
GSK Investigational Site, Layton, Utah, United States
Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 123
- Registration Number
- NCT03943095
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Canada
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 541
- Registration Number
- NCT03894969
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain